Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Biliary Atresia Therapeutics Market Growth From $214.37 Billion In 2026 To $257.23 Billion By 2030 At A CAGR Of 4.7%
The biliary atresia therapeutics market size has demonstrated significant growth in recent years. It is projected to increase from $1.02 billion in 2025 to $1.11 billion in 2026, at a compound annual growth rate (CAGR) of 8.3%. The expansion observed in the historic period can be attributed to several factors, including increasing awareness of pediatric liver disorders, improvements in kasai portoenterostomy outcomes, the expansion of pediatric hepatology services, the growing availability of liver transplantation programs, and advancements in supportive nutritional care.
The market for biliary atresia therapeutics is anticipated to experience substantial growth in the upcoming years. Its valuation is projected to reach $1.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.5%. This expansion during the projection period can be ascribed to several factors, including the emergence of new therapies designed to improve bile flow, a greater embrace of personalized treatment methods, the broadening of pediatric specialty care facilities, increased funding directed towards rare disease treatments, and advancements in sophisticated surgical intervention techniques. Key trends anticipated during the forecast period encompass progress in minimally invasive biliary surgical methods, a wider implementation of early diagnosis and intervention initiatives, an increased reliance on combination medication regimens to support liver function, the enlargement of pediatric liver transplantation programs, and a heightened emphasis on postoperative care and prolonged disease management.
Download A Free Sample Report For Comprehensive Market Insights:
Biliary Atresia Therapeutics Market Growth Momentum: Which Factors Are Influencing Demand?
The expansion of neonatal screening programs is projected to drive the growth of the biliary atresia therapeutics market in the future. Neonatal screening programs involve systematic public health initiatives that screen newborns shortly after birth to identify congenital, genetic, and metabolic disorders at an early stage. These programs are increasing due to rising government initiatives and healthcare policies focused on the early detection and timely treatment of congenital and genetic disorders in newborns. The broader implementation of neonatal screening programs allows for earlier identification of affected newborns, enabling prompt medical intervention and boosting the need for effective treatment strategies to manage disease progression and improve clinical outcomes. For instance, in March 2026, according to touchENDOCRINOLOGY, a UK-based peer-reviewed journal, the UK National Screening Committee (UK NSC) launched a consultation on newborn screening for biliary atresia, a rare liver disease affecting about 1 in 17,000 babies in the UK, where early detection is critical as treatment within the first 2 months significantly improves outcomes, though uncertainty remains about the effectiveness of population-wide screening. Thus, the expansion of neonatal screening programs is a key driver for the biliary atresia therapeutics market.
Biliary Atresia Therapeutics Market Segments: Where Are The Largest Growth Opportunities?
The biliary atresia therapeutics market covered in this report is segmented –
1) By Treatment Type: Surgical Procedures; Medication; Liver Transplantation; Other Treatment Types
2) By Age Group: Neonates; Infants; Pediatric Patients
3) By Route Of Administration: Oral; Injectable; Other Route Of Administrations
4) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Surgical Procedures: Kasai Portoenterostomy; Minimally Invasive Biliary Surgery; Robotic Assisted Biliary Surgery; Revision Surgical Procedures
2) By Medication: Corticosteroid Therapy; Antibiotic Therapy; Immunosuppressive Therapy; Bile Acid Therapy; Nutritional Supplement Therapy
3) By Liver Transplantation: Living Donor Liver Transplantation; Deceased Donor Liver Transplantation; Split Liver Transplantation; Pediatric Liver Retransplantation
4) By Other Treatment Types: Supportive Nutritional Care; Post Operative Care Management; Pediatric Hepatology Monitoring; Palliative Care Services
Clinical Trial Achieves Key Milestone In Evaluation Of Oral Therapy For Pediatric Liver Disease
Major companies operating in the biliary atresia therapeutics market are focusing on advancing clinical trials to develop innovative treatment options, such as ileal bile acid transporter (IBAT) inhibitor-based therapies to improve bile flow, reduce liver damage, and delay or prevent the need for liver transplantation in pediatric patients. IBAT inhibitor-based therapies refer to oral small-molecule drugs that work by blocking bile acid reabsorption in the intestine, thereby reducing toxic bile acid buildup in the liver, improving liver function, and supporting better clinical outcomes in cholestatic liver diseases such as biliary atresia. For instance, in May 2023, Mirum Pharmaceuticals, a US-based biopharmaceutical company, announced the completion of enrollment in its Phase 2b EMBARK study evaluating LIVMARLI (maralixibat) oral solution for pediatric patients with biliary atresia. The study is a global, double-blind, randomized, placebo-controlled trial designed to assess the efficacy and safety of the therapy in infants who had previously undergone the Kasai procedure (hepatoportoenterostomy). The EMBARK study represents the first completed randomized clinical trial of an ileal bile acid transporter (IBAT) inhibitor for biliary atresia, with topline results expected in the second half of 2023, and is expected to provide important insights into improving liver function and delaying disease progression in this rare pediatric liver disorder.
Biliary Atresia Therapeutics Market Major Participants And Competitive Dynamics
Major companies operating in the biliary atresia therapeutics market are Ipsen S.A.; Mirum Pharmaceuticals Inc.; CANbridge Pharmaceuticals Inc.
Access The Complete Biliary Atresia Therapeutics Market Report:
Biliary Atresia Therapeutics Market Largest Region By Revenue And Market Share
North America was the largest region in the biliary atresia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biliary atresia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.